[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572900":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":16,"studyPopulation":17,"armGroups":11,"interventions":11,"overallOfficials":11,"centralContacts":18,"locations":28,"responsibleParty":44,"collaborators":11,"id":46,"slug":11,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":11,"briefSummary":59,"conditions":60,"keywords":11,"overallStatus":62,"whyStopped":11,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Second Affiliated Hospital of Wenzhou Medical University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"imaging remission rate of anal fistula",null,"Treatment week 0 to 32",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":14,"timePerspective":15,"maskingInfo":11},"COHORT","RETROSPECTIVE","Participants in the study receive ustekinumab injections as part of routine medical care. The study just observes the efficacy retrospectively and does not interfere with treatment.","patients with perianal fistulizing Crohn's disease",[19,24],{"name":20,"role":21,"phone":22,"phoneExt":11,"email":23},"Yi Jiang","CONTACT","+86-13676715543","1009419972@qq.com",{"name":25,"role":21,"phone":26,"phoneExt":11,"email":27},"Luyan Fang","+86 13806552632","239542008@qq.com",[29],{"facility":30,"status":11,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"The Second Affiliated Hospital of Wenzhou Medical University","Wenzhou","Zhejiang","325000","China","CN",{"type":37,"coordinates":38},"Point",[39,40],120.66682,27.99942,{"lat":40,"lon":39},[43],{"name":25,"role":21,"phone":26,"phoneExt":11,"email":27},{"type":45,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100572900",false,"NCT06739278","Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease","Analysis for the Efficacy of Individual Treatment of Perianal Fistulizing Crohn's Disease With Ustekinumab","Inclusion Criteria:\n\n* Clinical diagnosis of Perianal Fistulizing Crohn's Disease\n* Receive ustekinumab therapy\n\nExclusion Criteria:\n\n* Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs\n* Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc.\n* Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc.\n* Combined with malignant tumor\n* Clinical data missing ≥30% or no follow-up","ALL","18 Years","65 Years",{"count":56,"type":57},119,"ESTIMATED","OBSERVATIONAL","This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.",[61],"Crohn Disease","NOT_YET_RECRUITING","2024-12-16",{"date":65,"type":66},"2024-12-18","ACTUAL",{"date":68,"type":57},"2024-12-20",{"date":70,"type":57},"2025-01-31",{"name":5,"class":6},1]